Acute hepatitis C: A retrospective study of 62 cases;Hépatites aiguës C: Etude rétrospective de 62 cas

Gastroenterologie Clinique et Biologique

Volumn 26, Issue 11, 2002, Pages 994-1000

  Morin, Thierry ^a   Pariente, Alexandre ^b  

^a CENTRE HOSPITALIER   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON;

ACUTE HEPATITIS; ADULT; ARTICLE; FEMALE; FOLLOW UP; HEPATITIS C; HOSPITAL INFECTION; HUMAN; IATROGENIC DISEASE; INTRAVENOUS DRUG ABUSE; MAJOR CLINICAL STUDY; MALE; PROGNOSIS; QUESTIONNAIRE; RETROSPECTIVE STUDY; SEX RATIO; SYMPTOM;

ACUTE DISEASE; ADOLESCENT; ADULT; AGE FACTORS; AGED; ANTIVIRAL AGENTS; CROSS INFECTION; DATA INTERPRETATION, STATISTICAL; FEMALE; FOLLOW-UP STUDIES; HEPATITIS C; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; QUESTIONNAIRES; RETROSPECTIVE STUDIES; RISK FACTORS; SEX FACTORS; SUBSTANCE ABUSE, INTRAVENOUS; TIME FACTORS;

EID: 17644432450     PISSN: 03998320     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Camma C, Almasio P, Craxi A. Interferon as treatment for acute hepatitis C. A meta-analysis. Dig Dis Sciences 1996;41:1248-55.
2. Conférence de consensus Hépatite C: Dépistage et traitement. Gastroenterol Clin Biol 1997;20:S202-S11.
3. Vogel W. Treatment of acute hepatitis C virus infection. J Hepatol 1999;31 (suppl. 1):189-92.
4. Guyader D, Lefeuvre C, Jacquelinet S, Prat M, Baudouard Y, Turlin B, et al. Epidémiologie de l'infection virale C chez 1304 sujets VHC positif. Gastroenterol Clin Biol 1998;22:375-80.
5. Mele A, Tosti ME, Marzolini A, Moiraghi A, Ragni P, Gallo C, et al. Prevention of hepatitis C in Italy: Lessons from surveillance of type-specific acute hepatitis. SEIEVA collaborating Group. J Viral Hep 2000;7:30-5.
6. Alter MJ. Epidemiology of hepatitis C. Hepatology 1997;26:62S-65S.
7. Roudot-Thoraval F, Bastie A, Pawlotsky JM, Dhumeaux D. Epidemiological factors affecting severity of hepatitis C virus-related liver disease: A french survey of 6664 patients. The Study Group for the Prevalence and the Epidemiology of Hepatitis C Virus. Hepatology 1997;26:485-90.
8. Cadranel JF, Di Martino V, Cesbron H, Cazier A, Demontis R, Coutarel P, et al. Epidémiologie de l'hépatite C dans un centre hospitalier général. Gastroenterol Clin Biol 2000;24:161-7.
9. Jaeckel E, Cornberg M, Wedemeyer H, Santantonio T, Mayer J, Zankel M, et al. Treatment of acute hepatitis C with Interferon alfa-2b. N Engl J Med 2001;345:1452-7.
10. Kenny-Walsh E, for the Irish Hepotology Research Group. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulins. N Engl J Med 1999;340:1228-33.
11. Wiese M, Berr F, Lafrenz M, Porst H, Oesen U. Low frequency of cirrhosis in a hepatitis C (genotype 1b) single-source outbreak in Germany: A 20-year multicenter study. Hepatology 2000;32:91-6.
12. Rodger AJ, Roberts S, Laginan A, Bowden S, Brown T, Croft N. Assessment of long term outcomes of community-acquired hepatitis C infection in a cohort with sera stored from 1971 to 1975. Hepatology 2000;32:582-7.
13. Villano SA, Vlahov D, Nelson KE, Cohn S, Thomas DL. Persistence of viremia and the importance of long-term follow-up after acute hepatitis C infection. Hepatology 1999;29:908-14.
14. Okuda K, Hayashi H, Yokozeki K, Kobayashi S, Kashima T, Irie Y. Acute hepatitis C among renal failure patients on chronic haemodialysis. J Gastroenterol Hepatol 1998;13:62-7.
15. Gursoy M, Gur G, Arslan H, Ozdemir N, Boyacioglu S. Interferon therapy in hemodialysis patients with acute hepatitis C virus infection and factors that predict response treatment. J Viral Hepat 2001;8:70-7.
16. Barrera JM, Bruguera M, Ercilla MG, Gil C, Celis R, Gil MP, et al. Persistant hepatitis C viremia after acute self-limiting post-transfusion hepatitis C. Hepatology 1995;21:639-44.
17. Seeff LB, Hollinger FB, Alter HJ, Wright EC, Cain CNB, Buskell ZJ, et al. Long-term mortality and morbidity of transfusion-associated non-A, non-B, and type C hepatitis: A National Heart, Lung, and Blood Institut collaborative study. Hepatology 2001;33:455-63.
18. Alberti A, Chemello L, Benvegnu L. Natural history of hepatitis C. J Hepatol 1999;31(suppl1):17-24.
19. Amoroso P, Rapicetta M, Tosti ME, Mele A, Spada E, Buonocore S, et al. Correlation between virus genotype and chronicity rate in acute hepatitis C. J Hepatol 1998;28:939-44.
20. Gerlach TJ, Diepolder. Symptomatic acute hepatitis C: When to treat? (abstract). Hepatology 1999;30:195A.
21. Santantonio T, Mazzola M, Guastadisegni A, Casalino C, Pastore G. A cohort study of acute hepatitis C virus (HCV) infection: Natural course and outcome (abstract). Hepatology 1999;30:205A.
22. Vogt M, Lang T, Frosner G, Klingler C, Sendl AF, Zeller A, et al. Prevalence and clinical outcome of hepatitis C infection in children who underwent cardiac surgery before implementation of blood donors screening. N Engl J Med 1999;341:866-70.
23. Orland JR, Wright TL, Cooper S. Acute hepatitis C. Hepatology 2001;33:321-7.
24. Alric L, Fort ML, Izopet J, Sandre K, Fontenelle P, Mularczyck M, et al. Etude des facteurs associés à la guérison spontanée de l'hépatite virale C (résumé). Gastroenterol Clin Biol 2000;24:A158.
25. Farci P, Shimoda A, Coiana A, Diaz G, Peddis G, Melpolder JC, et al. The outcome of acute hepatitis C predicted by the evolution of the quasispecies. Science 2000;288:339-44.
26. Ray SC, Wang YM, Laeyendecker O, Ticehurst JR, Villano SA, Thomas DL. Acute hepatitis C virus structural gene sequences as predictors of persistent viremia: Hypervariable region 1 as a decoy. J Virol 1999;73:2938-46.
27. Zibert A, Meisel H, Kraas W, Schultz A, Jung G, Roggendorf M. Early antibody response against hypervariable regionl is associated with acute self-limiting infections of hepatitis C virus. Hepatology 1997;25:1245-9.
28. Cucchiarini M, Kammer AR, Grabscheid B, Diepolder HM, Gerlach TJ, Grüner N, et al. Vigorous peripheral blood cytotoxic T cell response during the acute phase of hepatitis C virus infection. Cellular Immunology 2000;203:11-23.
29. Hoofnagle JH. Therapy for acute hepatitis C. N Engl J Med 2001;345:1495-7.
30. Sata M, Ide T, Noguchi S, Hashimoto O, Kumashiro R, Suzuki H, et al. Timing of IFN therapy initiation for acute hepatitis C after accidental needlestick. J Hepatol 1997;27:425-6.
31. Okuno T, Arai K, Shindo M. Efficacy of interferon therapy for patients who develop chronic hepatitis C after an acute course of hepatitis. J Hepatol 1997;27:767-8.
32. Conférence de Consensus Traitement de L'hépatite C, 27 et 28 février 2002, PARIS. www.anaes.fr.
33. Poynard T, Leroy V, Zarski JP. Meta-analysis of Interferon randomised trials in the treatment of viral hepatitis C: Effects of dose and duration. Hepatology 1996;24:778-89.
34. Takano S, Satomura Y, Omata M, and Japan acute hepatitis cooperative study group. Effects of interferon beta on Non-A, Non-B acute hepatitis: A prospective, randomised, controlled-dose study. Gastroenterology 1994;107:805-11.
35. Thevenot T, Regimbeau C, Ratziu V, Leroy V, Opolon P, Poynard T. Meta-analysis of interferon randomised trials in the treatment of viral hepatitis C in naive patients: 1999 Update. J Viral Hepat 2001;8:48-62.
36. Vogel W, Graziadei I, Umlauft F, Datz C, Hackl F, Allinger S, et al. High-dose interferon-alpha2b treatment prevents chronicity in acute hepatitis C: A pilot study. Dig Dis Sci 1996;41(suppl.):81S-5S.
37. Delwaide J, Bourgeois N, Gérard C, Wain E, Vaira D, Belaiche J. Treatment of acute hepatitis C with interferon a-2b prevents chronicity (abstract). Hepatology 1999;30:264A.
38. Rovere PA, Parrinello A. Acute HCV hepatitis and interferon treatment. J Hepatol 2001;34 (suppl1):178-9.